Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DDO | Q99489 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.32 |
| ▸ | ESR1 | P03372 | 4/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827872 | 0.81 | CYP1A2 (0.44) | CYP1A2CA9ESR2ESR1CA12 | |
| SCHEMBL5828010 | 0.81 | CYP1A2 (0.44) | CYP1A2CA9CA3CA6CA5A | |
| SCHEMBL5828094 | 0.76 | CA12 (0.36) | CYP1A2CA9CYP2A6FLT3KDM4E | |
| SCHEMBL3952850 | 0.72 | CYP1A2 (0.44) | CYP1A2CA9CA3CA5ACA14 | |
| SCHEMBL16585928 | 0.72 | KDM4E (0.33) | CYP1A2CYP2A6KDM4E | |
| SCHEMBL6630294 | 0.70 | CYP1A2 (0.41) | CYP1A2CA9CA3CA5ACA14 | |
| SCHEMBL28614473 | 0.69 | CYP1A2 (0.46) | CYP1A2KDM4EESR2ESR1CA1 | |
| SCHEMBL29678723 | 0.69 | CYP1A2 (0.56) | CYP1A2CA9CA3CA6CA5A | |
| SCHEMBL6812300 | 0.69 | CYP1A2 (0.56) | CYP1A2CA9CA3CA6CA5A | |
| SCHEMBL29890069 | 0.67 | CYP1A2 (0.54) | CYP1A2CA9CA3CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7025971-B2 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | WASHINGTON UNIVERSITY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6962791-B2 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | WASHINGTON UNIVERSITY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6872542-B1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | SIGA PHARMACEUTICALS, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-0730601-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | UNIV WASHINGTON (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030224468-A1 | By interacting with periplasmic molecular chaperones the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished | HULTGREN SCOTT (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030198992-A1 | By interacting with periplasmic molecular chaperones so the assemlbly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished; used in drug design | HULTGREN SCOTT (US) | 2003-10-23 | — | — | US | disclosed |
| US-6596504-B2 | Preventing, inhibiting or enhancing binding between at least one type of pilus subunit and at least one type of periplasmic molecular chaperone in the pilus-forming bacteria for therapy or prophylaxis of diseases | WASHINGTON UNIVERSITY | 2003-07-22 | — | — | US | disclosed |
| US-6548265-B2 | Preventing, inhibiting or enhancing binding between pilus subunits and periplasmic molecular chaperone | WASHINGTON UNIVERSITY | 2003-04-15 | — | — | US | disclosed |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-10-10 | — | — | US | disclosed |
| US-6420127-B1 | PREVENTION OF MICROORGANISMAL INFECTIONS; OBTAIN MEMBRANES, INCUBATE WITH MODULATORS, MONITOR MICROORGANISMAL INFECTIONS | WASHINGTON UNIVERSITY | 2002-07-16 | — | — | US | disclosed |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-03-21 | — | — | US | disclosed |
| US-6153396-A | DRUG SCREENING BY ADDING COMPOUND TO MIXTURE OF CHAPERONE AND PILUS SUBUNIT AND DETERMINING THE CHANGE IN BINDING; BACTERICIDES FOR URINARY TRACT INFECTIONS | SIGA PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6001823-A | NOVEL PYRANOSIDES WHICH ARE BELIEVED TO BE CAPABLE OF INTERACTING WITH PERIPLASMIC MOLECULAR CHAPERONES | WASHINGTON UNIVERSITY | 1999-12-14 | — | — | US | disclosed |
| EP-0730601-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014028-A9 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | — | 1995-08-10 | — | — | WO | disclosed |
| WO-1995014028-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034774-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | CYP1A2 3237/4885CA9 4782/4885CA3 4717/4885 |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | CYP1A2 3237/4885CA9 4782/4885CA3 4717/4885 |
| US-20030224468-A1 | By interacting with periplasmic molecular chaperones the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished | HSP90B1, HSPBP1, HSPB1 | CYP1A2 3379/4885CA9 4801/4885CA3 4695/4885 |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | CYP1A2 3237/4885CA9 4782/4885CA3 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.